Charles River Laboratories International, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-144.3M | $22.2M | $474.6M | $486.2M | $391.0M | $364.3M | $252.0M | $226.4M |
| Depreciation & Amortization | $403.3M | $361.7M | $314.1M | $303.9M | $265.5M | $234.9M | $198.1M | $161.8M |
| Depreciation | $177.6M | $190.2M | $176.7M | $157.3M | $140.7M | $123.0M | $108.6M | $96.9M |
| Amortization | $179.1M | $138.5M | $137.4M | $146.6M | $124.9M | $111.9M | $89.5M | $64.8M |
| Stock-Based Compensation | $71.1M | $69.9M | $72.0M | $73.6M | $71.5M | $56.3M | $57.3M | $47.3M |
| Net Cash from Operating Activities | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M | $546.6M | $480.9M | $441.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $219.2M | $233.0M | $318.5M | $324.7M | $228.8M | $166.6M | $140.5M | $140.1M |
| Business Acquisitions | $0 | $5.5M | $194.8M | $283.4M | $1.29B | $418.6M | $515.7M | $824.9M |
| Net Cash from Investing Activities | $-209.3M | $-245.1M | $-563.2M | $-607.9M | $-1.44B | $-601.5M | $-681.5M | $-955.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $360.7M | $119.2M | $24.2M | $38.7M | $40.7M | $24.0M | $18.1M | $13.8M |
| Net Cash from Financing Activities | $-536.7M | $-550.9M | $-85.5M | $-42.4M | $672.6M | $47.2M | $231.9M | $558.1M |
| Net Change in Cash | $10.4M | $-78.9M | $43.3M | $-5.1M | $13.2M | $-6.9M | $42.7M | $31.0M |
| Free Cash Flow | $518.5M | $501.6M | $365.4M | $294.9M | $532.0M | $380.0M | $340.4M | $301.1M |